A study to back accelerated approval is to start next year, but the prospect of seeing a fully greenlit Padcev before then looms large.

Seagen/Genmab’s confirmatory cervical cancer trial is toplined positive, putting up a fresh roadblock for Iovance’s accelerated filing plans.

With sales of the Amgen KRAS inhibitor flatlining an advisory panel is called to discuss its continued US approval.

Less than two months after a patient death CART-ddBCMA’s pivotal multiple myeloma trial is cleared to restart.

However, endometrial cancer remains a small use, and Jemperli has other ways to make a bigger splash.